1. Retrospective analysis of bevacizumab use in combination with irinotecan for recurrent glioblastoma: a single-institution experience. (February 2017) Authors: Besson, C.; Waissi, W.; Velten, M.; Nguyen Them, L.; Schott, R.; Prebay, D.; Etienne-Selloum, N. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. GENETIC PREDISPOSITION OF FAMILIAL HODGKIN LYMPHOMA. (12th June 2019) Authors: Khoury, E.; Mendola, A.; Choquet, S.; Landman‐Parker, J.; Veiga da Cunha, M.; Besson, C.; Limaye, N.; Poirel, H.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. INTERFERON‐FREE ANTIVIRAL TREATMENT IN B‐CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS‐C VIRUS INFECTION. (June 2017) Authors: Frigeni, M.; Visco, C.; Besson, C.; Rattotti, S.; Fontaine, H.; Goldaniga, M.; Visentini, M.; Torres, H.A.; Peveling‐Oberhag, J.; Rossotti, R.; Zaja, F.; Rigacci, L.; Merli, M.; Dorival, C.; Alric, L.; Piazza, F.; Gentile, M.; Ferrari, A.; Pirisi, M.; Tedeschi, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S280: B-CELL MALIGNANCIES TREATED WITH TARGETED DRUGS AND SARS-COV-2 INFECTION. A EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA). (23rd June 2022) Authors: Infante, M. S.; Salmanton-García, J.; Fernandez-Cruz, A.; Marchesi, F.; RÁČIL, Z.; Hanakova, M.; Jaksic, O.; Weinbergerova, B.; Besson, C.; Duarte, R.; Itri, F.; VALKOVIĆ, T.; Busca, A.; Guidetti, A.; GLENTHØJ, A.; Collins, G.; Bonuomo, V.; Sili, U.; Seval, G.; Machado, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗